Showing 71-80 of 333 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Prohormone convertase activity in human T1D pancreas tissue slices | University of Florida | Denise Drotar | Cures | 01-March-2025 to 29-February-2028 | $264.895,00 |
| Harnessing hematopoietic function in acute lymphoblastic leukemia to treat type 1 diabetes | Yale University | David Alagpulinsa | Cures | 01-March-2025 to 28-February-2030 | $991.634,17 |
| Longitudinal non-inasive monitoring of vascular remodeling using oxygen-sensing nanoprobes | Regents of the University of Michigan | Maria Coronel | Cures | 01-March-2025 to 28-February-2030 | $1.000.000,00 |
| Exploring the Effects of Beta Cell Regenerative Drugs on Cell Fate Decisions in Human Pancreatic Islets | Icahn School of Medicine at Mount Sinai | Esra Karakose | Cures | 01-March-2025 to 28-February-2030 | $999.999,00 |
| Development of simulation tools to support adaptation of automated insulin delivery algorithms across pregnancies complicated by type 1 diabetes | Rector & Visitors of the University of Virginia | Jacopo Pavan | Improving Lives | 01-March-2025 to 28-February-2027 | $189.316,00 |
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2026 | $845.444,86 |
| Targeted delivery of therapeutics to islet beta cells for preventing and treating diabetes | UT Southwestern | Juanzhu Yan | Cures | 01-March-2025 to 29-February-2028 | $285.000,00 |
| Employing PD-L1-Modified Biomaterials to Induce Islet Allograft Tolerance Following Perihepatic Transplantation in Nonhuman Primates | Regents of the University of Minnesota | Melanie Graham | Cures | 01-April-2025 to 31-March-2027 | $918.744,88 |
| Development of β-Cell Targeted Lipid Nanoparticle Therapeutics | The University of Chicago | Jacob Ryan Enriquez | Cures | 01-March-2025 to 29-February-2028 | $247.790,00 |
| Engineering hypoimmune cells for Type 1 Diabetes | New York Stem Cell Foundation, Inc. | Frederick J Monsma Jr | Cures | 01-May-2025 to 30-April-2028 | $1.498.415,83 |